辛妥珠單抗

維基百科,自由的百科全書
辛妥珠單抗
單株抗體
種類完整抗體
目標LOXL2英語LOXL2
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號1318075-13-6
IUPHAR/BPS
ChemSpider
  • none
UNII
化學資訊
化學式C6558H10134N1736O2037S50
摩爾質量147,492.33 g·mol−1

辛妥珠單抗INN:simtuzumab;開發代號:GS-6624)是一種人源化單株抗體,設計用於治療纖維化[1]它與LOXL2英語LOXL2結合併充當免疫調節劑[2][3]2016年1月,吉利德科學公司因缺乏療效而終止了針對特發性肺纖維化(IPF)患者的II期臨床研究。[4]

參考資料[編輯]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
  2. ^ Muir, Andrew J.; Levy, Cynthia; Janssen, Harry L. A.; Montano-Loza, Aldo J.; Shiffman, Mitchell L.; Caldwell, Stephen; Luketic, Velimir; Ding, Dora; Jia, Catherine; McColgan, Bryan J.; McHutchison, John G. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). 2019-02, 69 (2). ISSN 1527-3350. PMID 30153359. doi:10.1002/hep.30237. 
  3. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2). 
  4. ^ Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis. Gilead. 5 January 2016.